For much of the last three decades, treatment of degenerative knee disease has centered heavily on managing symptoms with anti-inflammatories, activity modification, lubricants and injections, while structural intervention was often reserved for more advanced disease. Focal cartilage defects had surgical options, but those came with their own tradeoffs in durability, complexity, and cost. That balance is shifting.
Cartilage defects are increasingly recognized not as isolated injuries but as the starting point of a progressive degenerative cascade. Osteoarthritis now affects nearly 600 million people worldwide, with the knee the most involved joint, according to an IHME study. In response, clinicians are intervening earlier and treating the knee as a structure worth preserving rather than merely a source of pain to be managed.
Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing GelrinC, a cell-free hydrogel implant for focal knee cartilage defects, in a market that is redefining what successful treatment looks like.
Two Forces Reshaping Knee Cartilage Care
Two developments are helping move structural repair up the treatment ladder.
The first is diagnostic. Specialized MRI sequences and high-resolution ultrasound can identify matrix damage, low-grade synovitis, and proteoglycan loss before those changes become visible on a standard X-ray, giving clinicians a clearer picture of structural deterioration earlier in the disease process.
The second is durability data on existing options. Microfracture remains the first-line cartilage procedure mostly for small defects because it is simple, familiar, and inexpensive, but it produces fibrocartilage rich in Type I collagen, and that tissue is prone to breaking down in less than two years. Cell-based procedures generate more durable hyaline-like tissue, though they require a first surgery, weeks of laboratory expansion, and a second surgery, with all-in costs per case that published estimates place in the approximately $45,000 e.
That leaves a market gap between a procedure that is easy to perform but temporary in efficacy and one that is more durable but costly and cumbersome to deliver.
A Matrix Built Around Controlled Resorption
GelrinC is composed of polyethylene glycol and denatured fibrinogen. It is delivered into the defect as a liquid, conforms to the shape of the lesion, and is cured into a solid matrix implant with ultraviolet light. The design intent is what distinguishes it: the implant is engineered to erode at a rate synchronized with the progressive creation of new cartilage tissue in the defect, so the matrix implant recedes, shrinking in size as new tissue forms.
The procedure takes roughly 10 minutes, can be performed using open or minimally invasive techniques, and requires no cell harvesting or return visit to the operating room.
Durability as the Endpoint That Matters
If the treatment goal is structural preservation above and beyond symptom control, multi-year outcomes become the relevant measure.
In a Phase II study of 56 patients across Northern Europe and Israel, GelrinC met its primary endpoints at 24 months, with the company reporting approximately 100% greater improvement in overall KOOS scores than microfracture. No serious adverse events were reported. Patients were followed for up to five years. The company also used MOCART, a nine-part MRI scoring system for cartilage repair tissue, as a predefined endpoint, reporting a mean score of 88.8 out of 100 at 24 months, consistent with near-complete structural repair.
Extending Toward Early Osteoarthritis
The same logic points beyond focal defects. Regentis has described earlier-stage formulations built on the Gelrin platform, including a GelrinP paste form for smaller joints such as the ankle, wrist, and elbow, and injectable thermo-responsive gel targeted at moderate osteoarthritis. Both remain preclinical, supported by animal studies.
In the near term, the company is working through a pivotal FDA trial under an Investigational Device Exemption, using a single-arm design with historical microfracture controls. Enrollment is targeted at 80 patients, with more than half recruited and treated, completion expected by approximately year end 2026, and PMA submission slated to begin at the end of 2027. European commercialization efforts are underway with CE Mark approval having already been achieved.
Whether GelrinC becomes part of the new standard depends on US trial results and regulatory clearance. Although the direction of orthopedic practice, toward earlier intervention and durable tissue restoration, is the environment the product was built for.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT
This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai
RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN
Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Glioblastoma is the deadliest form of brain cancer due to its aggressive growth rate. Most…
Roughly two-thirds of the world’s population lacks access to basic imaging technology, and the radiologist…
The FDA IND approval marks a pivotal step for the company's lead compound, known as…
Cancer care has evolved over the past decades and one would expect that the more…
In the United States alone, close to one million people are living with MS, with…
A nationwide survey conducted by the Commonwealth Fund has found that contrary to a common…